Micron Technology, Inc. vs F. Hoffmann-La Roche AG: Strategic Comparison
Key Differences at a Glance
| Field | Micron Technology, Inc. | F. Hoffmann-La Roche AG |
|---|---|---|
| Revenue | $37.4B | $77.2B |
| Founded | 1978 | 1896 |
| Employees | 53,000 | 112,774 |
| Market Cap | $1.11T | $327.5B |
| Headquarters | United States | Switzerland |
Quick Stats Comparison
| Metric | Micron Technology, Inc. | F. Hoffmann-La Roche AG |
|---|---|---|
| Revenue | $37.4B | $77.2B |
| Founded | 1978 | 1896 |
| Headquarters | Boise, Idaho, United States | Basel, Switzerland |
| Market Cap | $1.11T | $327.5B |
| Employees | 53,000 | 112,774 |
Micron Technology, Inc. Revenue vs F. Hoffmann-La Roche AG Revenue — Year by Year
| Year | Micron Technology, Inc. | F. Hoffmann-La Roche AG | Leader |
|---|---|---|---|
| 2025 | $37.4B | $77.2B | F. Hoffmann-La Roche AG |
| 2024 | $25.1B | $75.9B | F. Hoffmann-La Roche AG |
| 2023 | $15.5B | $75.9B | F. Hoffmann-La Roche AG |
Business Model Breakdown
Overview: Micron Technology, Inc. vs F. Hoffmann-La Roche AG
This in-depth comparison examines Micron Technology, Inc. and F. Hoffmann-La Roche AG across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching Micron Technology, Inc. on its own, evaluating F. Hoffmann-La Roche AG, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between Micron Technology, Inc. and F. Hoffmann-La Roche AG is widest.
On the headline numbers, Micron Technology, Inc. reports annual revenue of $37.4B against $77.2B for F. Hoffmann-La Roche AG, while their respective market capitalizations stand at $1.11T and $327.5B. Micron Technology, Inc. is headquartered in United States and F. Hoffmann-La Roche AG operates from Switzerland, and those different home markets shape how each company competes.
Micron Technology, Inc.: Micron Technology, Inc. is a public company listed on NASDAQ under ticker MU. Micron makes money by designing and manufacturing memory and storage semiconductors sold into data centers, PCs, smartphones, autos, industrial systems, and consumer storage channels.
F. Hoffmann-La Roche AG: Roche is not just a drug company with a diagnostics side business. Its strategic identity is an integrated healthcare model: test the patient, identify the biology, treat with a targeted therapy, and use outcome data to improve the next development cycle.
Business Models: How Micron Technology, Inc. and F. Hoffmann-La Roche AG Make Money
Micron Technology, Inc. and F. Hoffmann-La Roche AG pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between Micron Technology, Inc. and F. Hoffmann-La Roche AG.
Micron Technology, Inc. business model: Micron makes money by designing and manufacturing memory and storage semiconductors sold into data centers, PCs, smartphones, autos, industrial systems, and consumer storage channels.
F. Hoffmann-La Roche AG business model: Roche makes money from branded prescription medicines, biologics, oncology and specialty drugs, diagnostic instruments, diagnostic reagents, sequencing and molecular testing, diabetes care products, and clinical data assets. Pharmaceuticals drive the largest share of sales, while Diagnostics adds recurring reagent revenue and supports personalized healthcare.
Competitive Advantage: Micron Technology, Inc. vs F. Hoffmann-La Roche AG
The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of Micron Technology, Inc. stack up against those of F. Hoffmann-La Roche AG.
Micron Technology, Inc. competitive advantage: Micron's edge is process technology, HBM and advanced DRAM execution, manufacturing scale, customer qualification, and a balance sheet built for memory cycles.
F. Hoffmann-La Roche AG competitive advantage: Roche's advantage is the combination of drug development, diagnostics, Genentech biotechnology depth, companion diagnostic capability, and oncology data assets from Foundation Medicine and Flatiron Health. Competitors can match pieces of this model, but few can connect medicines, tests, and real-world data at similar scale.
Growth Strategy: Where Micron Technology, Inc. and F. Hoffmann-La Roche AG Are Headed
Future prospects matter as much as current results. The growth strategies below explain how Micron Technology, Inc. and F. Hoffmann-La Roche AG each plan to expand from here.
Micron Technology, Inc. growth strategy: Micron Technology, Inc.'s growth strategy centers on this advantage: Micron's edge is process technology, HBM and advanced DRAM execution, manufacturing scale, customer qualification, and a balance sheet built for memory cycles.
F. Hoffmann-La Roche AG growth strategy: Roche is investing in late-stage medicines, diagnostics platforms, sequencing, companion diagnostics, real-world evidence, and selective acquisitions that strengthen oncology, immunology, neuroscience, and cardiovascular-metabolic disease areas.
Financial Picture: Micron Technology, Inc. vs F. Hoffmann-La Roche AG
A closer look at the financial trajectory of Micron Technology, Inc. and F. Hoffmann-La Roche AG rounds out the comparison.
Micron Technology, Inc.: Micron Technology, Inc. reported FY2025 revenue of $37.378B and net income of $8.539B.
F. Hoffmann-La Roche AG: Roche reported CHF 61.5 billion in 2025 group sales. Pharmaceuticals sales were CHF 47.7 billion and Diagnostics sales were CHF 13.8 billion. Core operating profit was CHF 21.8 billion, and R&D core investments were CHF 12.2 billion. For USD comparability, this profile converts CHF 61.5 billion at 1 CHF = 1.25506 USD.
Company-Specific SWOT Notes
Micron Technology, Inc.
HBM and advanced DRAM demand put Micron in the center of AI server growth.
Memory manufacturing requires very high capital spending and exposes Micron to depreciation and utilization swings.
AI servers, high-performance computing, and memory-rich client devices can raise demand per system.
Oversupply, price declines, export controls, and competitor capacity can rapidly compress margins.
F. Hoffmann-La Roche AG
Roche's advantage is the combination of drug development, diagnostics, Genentech biotechnology depth, companion diagnostic capability, and oncology data assets from Foundation Medicine and Flatiron Health.
Roche wins by combining medicines, diagnostics, biomarkers, and oncology data into a precision-healthcare model competitors struggle to copy.
The biggest risk is that biosimilar erosion and pricing pressure outrun the replacement power of Roche new launches and late-stage pipeline.
Roche is investing in late-stage medicines, diagnostics platforms, sequencing, companion diagnostics, real-world evidence, and selective acquisitions that strengthen oncology, immunology, neuroscience, and cardiovascular-metabolic disease areas.
Head-to-Head Scorecard
| Category | Winner | Why |
|---|---|---|
| Revenue Scale | F. Hoffmann-La Roche AG | F. Hoffmann-La Roche AG reports the larger revenue base ($77.2B), which serves as a core operational scale signal. |
| Profitability Potential | Comparable | Both organizations prioritize market penetration or are at equivalent reporting tiers. |
| Company Age | F. Hoffmann-La Roche AG | Founded in 1978 vs 1896. The earlier pioneer typically commands longer historical institutional legacy. |
| Innovation Moat | Tied | Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity. |
| Scale (Employees) | F. Hoffmann-La Roche AG | A significantly larger reported workforce supports enhanced global distribution capability. |
| Market Cap | Micron Technology, Inc. | Higher public valuation denotes greater forward-looking investor conviction in earnings potential. |
| Future Outlook | Tied | Strategic auditing assesses that both maintain defensive leadership vectors within their core market clusters. |
Who Wins Each Category?
F. Hoffmann-La Roche AG reports the larger revenue base ($77.2B), which serves as a core operational scale signal.
Both organizations prioritize market penetration or are at equivalent reporting tiers.
Founded in 1978 vs 1896. The earlier pioneer typically commands longer historical institutional legacy.
Higher aggregate count of major acquisitions and key R&D releases indicates a more active technology absorption velocity.
A significantly larger reported workforce supports enhanced global distribution capability.
Who Wins: Micron Technology, Inc. or F. Hoffmann-La Roche AG?
Reviewed by Swet Parvadiya, May 2026 - Author Profile
Our analysts compile business strategy profiles from public financial filings, press releases, and analyst reports. Each profile is reviewed for accuracy before publication by our editorial desk and updated on a rolling basis.
Frequently Asked Questions: Micron Technology, Inc. vs F. Hoffmann-La Roche AG
Is Micron Technology, Inc. better than F. Hoffmann-La Roche AG?
Verdict: Between Micron Technology, Inc. and F. Hoffmann-La Roche AG, F. Hoffmann-La Roche AG is the stronger overall option based on higher annual revenue. The decision still depends on which factors matter most for your needs, but on the weight of the evidence above, F. Hoffmann-La Roche AG comes out ahead in this Micron Technology, Inc. vs F. Hoffmann-La Roche AG comparison.
Who earns more — Micron Technology, Inc. or F. Hoffmann-La Roche AG?
F. Hoffmann-La Roche AG earns more with $77.2B in annual revenue versus Micron Technology, Inc.'s $37.4B. F. Hoffmann-La Roche AG leads on total revenue based on latest verified figures.
Which company has higher revenue — Micron Technology, Inc. or F. Hoffmann-La Roche AG?
Micron Technology, Inc. reported $37.4B, while F. Hoffmann-La Roche AG reported $77.2B. The revenue leader is F. Hoffmann-La Roche AG based on latest verified figures.
Micron Technology, Inc. revenue vs F. Hoffmann-La Roche AG revenue — which is higher?
Micron Technology, Inc. revenue: $37.4B. F. Hoffmann-La Roche AG revenue: $37.4B. F. Hoffmann-La Roche AG has the larger revenue base of the two companies.
Sources & References
- SEC EDGAR: Micron Technology, Inc. Annual Filings (10-K, 8-K)
- Micron Technology, Inc. Corporate Website
- Micron Technology, Inc. Annual Report 2025 - Revenue and Financial Data
- sec.gov
- investors.micron.com
- investors.micron.com
- F. Hoffmann-La Roche AG Corporate Website
- F. Hoffmann-La Roche AG Annual Report 2025 - Revenue and Financial Data
- roche.com
- roche.com
- assets.roche.com
- roche.com
- stockanalysis.com
- ofx.com